跳至主要内容
临床试验/JPRN-UMIN000014222
JPRN-UMIN000014222已完成4 期

ow-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis; a multicentre, open label, randomised control trial - LoVAS

Chiba University Hospital0 个研究点目标入组 140 人开始时间: 2014年8月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
140

研究概览

简要总结

Remission rates: Low-dose group 71% vs High-dose group 69%

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • The presence of any of the following will preclude patient inclusion: (1) Prior treatment for ANCA-associated vasculitis before trial entry (2) ANCA-associated vasculitis related glomerulonephritis (eGFR<15ml/min) or alveolar hemorrhage (oxygen inhalation >2L/min) (3) Presence of another multisystem autoimmune disease (4) Known infection with HIV; a past or current history of hepatitis B virus or hepatitis C virus infection (5) Desire to bear children, pregnancy or lactating (6) History of malignancy within the past 5 years or any evidence of persistent malignancy (7) Ongoing or recent (last 1 year) evidence of active tuberculosis (8) Severe allergy or anaphylaxis to monoclonal antibody therapy (9) Any concomitant condition anticipated to likely require oral systemic glucocorticoids, immunosuppressants, biologics, plasma exchange or IVIg (10) Any biological B cell depleting agent (such as rituximab or belimumab) within the past 6 months (11) Other conditions, in the investigator's opinion, inappropriate for the trial entry

研究者

相似试验